Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HBB | P68871 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanine SCHEMBL13516878 | 0.93 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Guanine SCHEMBL4577520 | 0.92 | KDM4E (0.43) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Guanine SCHEMBL2636585 | 0.86 | KDM4E (0.38) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Guanine SCHEMBL5259 | 0.85 | ALDH1A1 (0.61) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Guanine SCHEMBL4658042 | 0.85 | ALDH1A1 (0.61) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Guanine SCHEMBL865492 | 0.83 | ALDH1A1 (0.59) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Guanine SCHEMBL4063556 | 0.83 | ALDH1A1 (0.59) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Guanine SCHEMBL2895087 | 0.83 | ALDH1A1 (0.59) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Guanine SCHEMBL21611717 | 0.83 | ALDH1A1 (0.59) | KDM4EALDH1A1HSD17B10LMNAGLA | |
| Guanine SCHEMBL28373862 | 0.83 | ALDH1A1 (0.59) | KDM4EALDH1A1HSD17B10LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10913946-B2 | RNA modulating oligonucleotides with improved characteristics for the treatment of Duchenne and Becker muscular dystrophy | BIOMARIN TECHNOLOGIES B.V. (NL) | 2021-02-09 | — | — | US | disclosed |
| US-20190194656-A1 | RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Duchenne and Becker Muscular Dystrophy | BIOMARIN TECHNOLOGIES B.V. (NL) | 2019-06-27 | — | — | US | disclosed |
| CN-109790535-A | Prevent the method and composition of concatemerization during template switch | 新英格兰生物实验室公司 | 2019-05-21 | — | — | CN | disclosed |
| US-8168604-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | AVI BIOPHARMA INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8030292-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | AVI BIOPHARMA INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-8030291-B2 | Antisense antiviral compounds and methods for treating a filovirus infection | AVI BIOPHARMA INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20090239213-A1 | Identifying a target polynucleotide | LINGVITAE AS (NO) | 2009-09-24 | — | — | US | disclosed |
| US-20090186848-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | SAREPTA THERAPEUTICS, INC. | 2009-07-23 | — | — | US | disclosed |
| US-20090186847-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | SAREPTA THERAPEUTICS, INC. | 2009-07-23 | — | — | US | disclosed |
| US-20090186849-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | SAREPTA THERAPEUTICS, INC. | 2009-07-23 | — | — | US | disclosed |
| WO-2006040550-A1 | IDENTIFYING A TARGET POLYNUCLEOTIDE | LINGVITAE AS (NO) | 2006-04-20 | — | — | WO | disclosed |
| EP-0721458-A1 | BIOPOLYMER SYNTHESIS UTILIZING SURFACE ACTIVATED, ORGANIC POLYMERS | BECKMAN INSTRUMENTS, INC. (US) | 1996-07-17 | — | — | EP | disclosed |
| EP-0700449-A1 | INVERSE LINKAGE OLIGONUCLEOTIDES FOR CHEMICAL AND ENZYMATIC PROCESSES | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-13 | — | — | EP | disclosed |
| EP-0677057-A1 | BIOPOLYMER SYNTHESIS UTILIZING SURFACE ACTIVATED, ORGANIC POLYMERS | BECKMAN INSTRUMENTS, INC. (US) | 1995-10-18 | — | — | EP | disclosed |
| WO-1995014029-A1 | PROTECTED OLIGONUCLEOSIDES AND THEIR USE IN HIGH YIELDING SYNTHESIS OF DNA AND ANTISENSE DNA | BECKMAN INSTRUMENTS, INC. (US) | 1995-05-26 | — | — | WO | disclosed |
| WO-1995011912-A2 | BIOPOLYMER SYNTHESIS UTILIZING SURFACE ACTIVATED, ORGANIC POLYMERS | BECKMAN INSTRUMENTS, INC. (US) | 1995-05-04 | — | — | WO | disclosed |
| WO-1995009176-A1 | BIOPOLYMER SYNTHESIS UTILIZING SURFACE ACTIVATED, ORGANIC POLYMERS | BECKMAN INSTRUMENTS, INC. (US) | 1995-04-06 | — | — | WO | disclosed |
| EP-0637314-A1 | N-ACYLATED 2'-DEOXYCYTIDINES USEFUL IN OLIGONUCLEOTIDE SYNTHESIS | BECKMAN INSTRUMENTS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1994024312-A2 | INVERSE LINKAGE OLIGONUCLEOTIDES FOR CHEMICAL AND ENZYMATIC PROCESSES | BECKMAN INSTRUMENTS, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| WO-1993022326-A1 | PROTECTING GROUPS USEFUL IN OLIGONUCLEOTIDE SYNTHESIS | BECKMAN INSTRUMENTS, INC. (US) | 1993-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186848-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | RNGTT, POLM, EIF2AK2 | KDM4E 4187/4885ALDH1A1 4508/4885HSD17B10 4333/4885 |
| US-20090186849-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | RNGTT, POLM, EIF2AK2 | KDM4E 4187/4885ALDH1A1 4508/4885HSD17B10 4333/4885 |
| US-20090186847-A1 | ANTISENSE ANTIVIRAL COMPOUNDS AND METHODS FOR TREATING A FILOVIRUS INFECTION | RNGTT, POLM, EIF2AK2 | KDM4E 4187/4885ALDH1A1 4508/4885HSD17B10 4333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.